Can You Have Fatty Liver with Normal Liver Tests? What You Need to Know

An alarming 30-40% of the global adult population is reported to have Fatty Liver Disease, now referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with the highest burden found in the Americas and South-East Asia. The disease burden has continuously increased over time from 26% in 2005 to the current figures owing to several factors, particularly the changes in lifestyle, obesity, eating habits, and metabolic health concerns.

In India, the estimated MASLD prevalence is even more concerning, with 38.6% adults and 35.4% children being affected by the disease. With millions affected by fatty liver, it is a major national health crisis. Even more worrying is the silent nature of fatty liver. Several individuals may have fatty liver without any noticeable symptoms while their routine liver function tests remain within normal range even when they have underlying liver disease.

So, to answer the question we started with, ‘Can you have Fatty Liver even when your Liver Function Tests come back normal?’ Yes. You can.

In this blog, we shall delve into the reasons as to why this may happen, help understand how hepatologists actually diagnose Fatty Liver, and equip you with actionable strategies for liver health protection.

Understanding MASLD (Fatty Liver Disease)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a condition in which excess fat accumulates in the liver due to one or more metabolic risk factors such as:

Obesity or Excess Weight
Type 2 Diabetes
High Blood Pressure
Abnormal Cholesterol or Triglycerides Levels
Insulin Resistance & Other Metabolic Abnormalities

Unlike Alcohol-Related Liver Disease (ALD), people who have never consumed alcohol too can develop MASLD due to the above-listed metabolic risk factors. This is why fatty liver is increasingly understood as a metabolic health condition affecting the liver, rather than simply a liver disease.

MASLD exists on a spectrum and differs in severity – some individuals may have liver fat without significant damage while others may develop Metabolic Dysfunction-Associated Steatohepatitis (MASH). In MASH, the accumulation of fat is accompanied by inflammation and injury to liver cells. Over time, this can cause fibrosis (scarring) and, in some people, progress to advanced fibrosis, cirrhosis and related complications, including liver cancer.

MASLD is now one of the most common chronic liver diseases globally and is the major cause of advanced liver disease and liver-related complications. Its association with obesity, diabetes and other metabolic conditions also contributes to increased overall health risks. Proactive risk profiling, early diagnosis, and lifestyle-integrated treatments are essential for protecting the organ in the long run and preserving its function.

What Defines a Normal Liver Test?

Liver Function Tests (LFTs) are a group of blood tests that measure substances such as liver enzymes, bilirubin, and proteins in the blood. They can provide important information about liver injury, bile flow, and certain aspects of liver function while helping monitor liver disease/ damage.

Liver specialists recommend LFTs for a number of reasons including:

Checking if the liver is performing its functions

Screening for liver infections like hepatitis
Monitor liver disease progression
Monitor if treatment is working
Monitor possible side effects of medications
Identifying signs of serious diseases like cirrhosis

Note that a normal LFT may not necessarily mean that the liver is completely healthy. Liver enzymes can remain within the normal range in some people with fatty liver, and even some people with significant fibrosis.

How Common is Fatty Liver Among People with Normal Liver Tests?

Data suggests that nearly 74% of individuals with ‘normal’ Liver Tests show signs of MASLD. One study found that patients with NAFLD or NASH and normal ALT (alanine aminotransferase) values did not have any significant difference in inflammation or fibrosis on biopsy when compared with those who had elevated ALT levels.

Liver Function Tests, by themselves, can be misleading and create a false sense of security among individuals who see normal values. Hepatologists insist that an individual’s LFTs be evaluated alongside the individual’s metabolic profile, medical history, and imaging/ non-invasive fibrosis assessment.

Why Do LFTs Not Always Detect Fatty Liver?

The main limitation of Liver Function Tests is that it measures liver enzymes in the blood that may indicate inflammation and liver injury but not necessarily fat accumulation. So, an individual could have fat building up in their liver without active cellular damage or inflammation.

In some people with MASLD, liver enzymes may remain normal despite the presence of liver fat or even significant fibrosis. This means that relying on ALT and AST levels alone may provide a false sense of reassurance, particularly in people who have risk factors such as obesity, type 2 diabetes, insulin resistance or other metabolic conditions.

There is also no single LFT value that can reliably determine how much fat is present in the liver or whether significant scarring has developed. The severity of MASLD therefore cannot be assessed based on liver enzyme levels alone.

So, How is Fatty Liver Actually Detected?

To accurately detect and diagnose MASLD, hepatologists look at the complete clinical picture of the patient including:

Individual and family medical history
Metabolic profile to understand risk factors
Blood test results
Imaging & non-invasive tests to assess liver fat and fibrosis

To obtain additional information, the doctor may also recommend an abdominal ultrasound, fibrosis scoring, or the gold standard – Liver FibroScan. When these imaging and non-invasive tests are inconclusive, doctors also recommend liver biopsies to assess liver fat and fibrosis.

Actionable Steps to Protect Your Liver

A normal LFT result should not be a reason to ignore liver health, particularly if you have obesity, diabetes, insulin resistance or other metabolic risk factors. The good news is that MASLD is often responsive to meaningful lifestyle changes, particularly when it is identified early.

Targeted Weight Loss

For obese or overweight individuals, a 5-10% gradual and sustainable weight loss is highly recommended to reduce liver fat and improve inflammation. Even a modest reduction in body weight is highly beneficial for high-risk individuals. Remember the goal is not to rapidly lose weight or engage in extreme/ crash dieting but to adopt a sustainable approach that can be maintained overtime.

Regular Physical Activity

Regular physical activity of upto 30 mins every day benefits your liver significantly. Simple physical activities like brisk walking, cycling, swimming, resistance training, or aerobic exercises are adequate. Choose activities that you enjoy and engage in them every day.

Lifestyle Modifications

Making sustainable lifestyle changes such as the following helps a great deal in managing fatty liver:

Correct your sleep cycle.
Get restful sleep each night.
Maintain an active, healthy lifestyle.
Exercise for 30 minutes daily.
Avoid crash diets and adopt clean eating habits.
Completely quit smoking and alcohol.
Stay well hydrated.

Since your liver health is closely linked to your overall metabolic health, it is important to manage conditions like Type 2 diabetes, high cholesterol and high BP. For this,

Dietary Shifts

There is no single fatty liver diet, but making overall improvements to the quality and quantity of food can help improve your liver health.

Include vegetables, fruits and whole foods
Eat whole grains and high-fibre foods
Get adequate protein from healthy sources
Add Nuts, seeds and other unsaturated fat sources to your diet
Avoid processed foods, sugary items, sugar-sweetened beverages, refined carbohydrates, and excessive saturated fat.
Portion control is also important

Proactive Risk Profiling

Because LFTs alone cannot reliably rule out fatty liver or significant fibrosis, people with metabolic risk factors may benefit from a more comprehensive assessment by a hepatologist. Analysing factors such as BMI, body fat, waist circumference, diabetes, lipid profile, blood tests, and non-invasive liver assessments (such as FibroScan), the doctor will evaluate whether there is a risk of progressive liver damage. Based on this risk profile, they may recommend measures to take control of your liver and overall health proactively.

Concluding Thoughts: Pay Attention to Your Liver Before You Start Seeing Abnormal Test Results

Fatty Liver Disease, now called MASLD, is a silent threat because it remains asymptomatic and does not show up in your regular Liver Function Tests for years. When symptoms start to appear, the liver may already be seriously damaged. This means that waiting for symptoms or abnormal blood test results may delay the identification and management of liver disease.

Regular monitoring is particularly important for people who already have fatty liver, diabetes, obesity or other metabolic risk factors. A proactive approach that combines risk profiling, early identification, effective MASLD management, and sustainable lifestyle changes can reduce the risk of disease progression and protect long-term liver function.

Don’t wait for abnormal liver test results to show up to start taking your liver health seriously! Know your risk, get assessed, and take early action.

About the Author

Dr. KN Chandan Kumar is the Director of Hepatology andTransplant Hepatology at KIMS Hospitals, Hyderabad, with over 15 years of experience in managing complex liver diseases. He is among the early DM-qualified Hepatologists from the Institute of Liver and Biliary Sciences (ILBS), New Delhi, and has received international training in Transplant Hepatology at Mount Sinai Medical Center, New York, and Liver Intensive Care at King’s College Hospital, London. His areas of expertise include acute-on-chronic liver failure, portal hypertension and liver transplantation.

References:

Danpanichkul P, Souza M, Tothanarungroj P, Ahmed A, Kim D. Global Epidemiological Patterns and Disease Burden of MASLD, MetALD, and ALD. Clin Mol Hepatol. ;0..

Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14. PMID: 36517002; PMCID: PMC10029957.

Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. J Clin Exp Hepatol. 2022 May-Jun;12(3):818-829. doi: 10.1016/j.jceh.2021.11.010. Epub 2021 Nov 25. PMID: 35677499; PMCID: PMC9168741.

Lominadze Z, Kallwitz ER. Misconception: You Can't Have Liver Disease With Normal Liver Chemistries. Clin Liver Dis (Hoboken). 2018 Nov 6;12(4):96-99. doi: 10.1002/cld.742. PMID: 30988921; PMCID: PMC6385914.